The Correlated Research Of IL-33 And Rheumatoid Arthritis

Rheumatoid arthritis is characterized by erosive synovitis of an autoimmune disease, eventually lead to the destruction of bone and cartilage, its main clinical feature is the symmetry number of peripheral joint pain, swelling and functional decline. Many cytokines are involved in the pathogenesis of RA. In the collagen induced arthritis(CIA) model, by intraperitoneal injection of recombinant IL-33 can lead to increased symptoms of arthritis, this provides a premise to study IL-33 associated with the RA, although RA synovial expression of IL-33 have been reported in the literature, however, RA synovial fibroblasts, synovial fluid and serum IL-33 expression have not yet been reported.[Objective] To investigate the synovium, synovial fibroblasts, synovial fluid and serum whether or not there is the interleukin-33 (IL-33) expression in patients with RA and to analysis the correlation between the serum IL-33 levels and clinical and serologic features .[Methods] Using Immunohistochemistry and immunofluorescence to understand synovial tissue , synovial fibroblasts, synovial fluid and serum whether there is IL-33 expression in patients with RA; relative quantitative analysising the mRNA expression level of IL-33 in patients with RA; to measure synovial fluid and serum levels of IL-33 expression in patients with RA by enzyme-linked immunosorbent assay( ELISA).[Results] IL-33 expresses in synovial tissues of RA patients, and in RA synovial fibroblasts the IL-33 expresses in the nucleus;IL-33 mRNA expression levels in synovial fibroblasts of RA patients is higher than in OA patients'; IL-33 expresses in RA synovial fluid of some patients with RA, the positive rate was 41.9%, IL-33 also expresses in some RA patients'serum, the positive rate was 35%, and there are some correlation between the serum IL-33 levels of RA patients with some of autoantibodies in vivo (such as anti-CCP antibodies, anti-MCV antibodies, RF, HRFIgG), however, the levels of IL-33 of the serum and synovial fluid in the same RA patients were no significant difference; infliximab treatment could be effectively reduce the serum IL-33 levels of RA patients.[Conclusion]1,IL-33 expresses in synovial tissues, synovial fibroblasts, synovial fluid and serum of RA patients, suggesting that IL-33 has a certain role in the pathogenesis of RA.2,IL-33 is correlated with autoantibodies of patients with RA, suggesting that IL-33 may have a certain role in the process of autoantibodies production,in addition, as these antibodies are indicators of poor prognosis in RA, suggesting that IL-33 perhaps one of the factors of poor prognosis of RA .3,Infliximab (TNF-αmonoclonal antibody) can effectively reduce the serum IL-33 levels of patients with RA, suggesting that TNF-αmonoclonal antibody may be able to treat RA through the IL-33 pathway.